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 Prevention of sudden cardiac 
arrest in dialysis patients: can we 
do more to improve outcomes ? 
 Bessie A.  Young 1 , 2 
 Sudden cardiac arrest (SCA) is a leading cause of cardiac-associated 
mortality in dialysis patients. Risk factors unique to hemodialysis 
patients include abnormal electrolytes, large-volume ultrafiltration, and 
prior history of cardiac disease. Few randomized controlled trials of 
standard cardiac interventions have been completed in dialysis patients. 
Observational studies suggest that modification of the dialysis 
prescription may be one place to intervene. Prospective research is 
needed to determine mechanisms of SCA in hemodialysis patients. 
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 Cardiac disease remains the primary cause 
of death among dialysis patients (84.5 per 
1000 patient-years) and accounts for 
39.2 % of all deaths. 1 Mortality associated 
with sudden cardiac death or sudden car-
diac arrest (SCA) accounts for 58.6 % of 
cardiac-related deaths (49.5 per 1000 
patient-years). 1 As expected, SCA-associ-
ated death is higher among the elderly and 
those with a cardiac history and among 
whites compared with blacks and other 
minorities. 1 In addition, SCA is known to 
occur more oft en on the fi rst dialysis day 
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aft er a 2-day hiatus, 2,3 with the risk being 
highest during and immediately after 
dialysis. 4 SCA is five- to 15-fold more 
likely to result from either ventricular 
fi brillation or ventricular tachycardia dur-
ing or immediately aft er dialysis, whereas 
a pulseless electrical activity arrest is more 
likely to occur before dialysis. 3 Rates of 
sudden death per dialysis session range 
from 3.4 in 100,000 3 to 7.0 in 100,000 5 
dialysis sessions in the outpatient setting 
and to 12.5 in 100,000 dialysis sessions in 
hospital-based dialysis units. 5 
 Risk factors associated with SCA 
include older age, 6 history of underlying 
diabetes, 6,7 increased inflammation, 8 
recent hospitalization, 6 low-potassium 
dialysate, 6 malnutrition, 6 use of a cathe-
ter for dialysis access, 6 left  ventricular 
hypertrophy, 9 increased levels of brain 
natriuretic peptide or N-terminal-pro-
B-type natriuretic peptide (nT-pro-BNP), 10 
rapid changes in electrolytes or large-
volume fl uid removal, and prior history 
of cardiac disease or arrhythmia. 4,6 In a 
landmark paper, Karnik and colleagues 
reported that a low-potassium bath of 0 
or 1 mequiv. per liter was associated with 
a greater risk of cardiac arrest (17.1 % 
versus 8.8 % ); however, low-K   +   dialysate 
baths did not account for all cases of car-
diac arrest. 6 Additional proposed SCA 
triggers include reduced left  ventricular 
function, ventricular ectopy, interstitial 
fi brosis due to chronic uremia, calcium 
and phosphate deposition, chronic fl uid 
overload, and generalized electrical 
instability due to fl uid shift s, acid / base 
abnormalities, and other electrolyte 
abnormalities. 11 – 13 Myocardial stunning, 
which is thought to occur with each dialysis 
session and is due to excessive volume 
and electrolyte shift s, may also contrib-
ute to the increased risk of SCA in dial-
ysis patients. 13,14 
 Few randomized controlled trials have 
evaluated interventions aimed at reducing 
SCA in dialysis patients. Observational 
data suggest that use of beta-blockers, 
angiotensin-converting enzyme inhibi-
tors, or angiotensin receptor blockers has 
been associated with decreased overall 
mortality. 15 In addition, automatic defi -
brillator placement in dialysis units has 
not been shown to be associated with 
improved survival of hemodialysis 
patients aft er SCA. 3,16 No randomized 
controlled trial of implantable cardiac 
defi brillators (ICDs) in dialysis patients 
has ever been completed; however, obser-
vational studies have shown that ICD 
placement was associated with a 42 % 
reduction in mortality in comparison with 
those without ICD placement. 17 Implant-
able defi brillators are sorely underutilized 
in dialysis patients, 17,18 and the Implant-
able Cardioverter Defi brillators in Dialysis 
Patients (ICD2) trial is a current rand-
omized controlled trial enrolling approx-
imately 200 dialysis patients aged 50 – 80 
years with prevention of SCA as the pri-
mary end point. 19 
 Now, Pun and colleagues 20 (this issue) 
describe a case-control study that evalu-
ated potentially modifi able risk factors for 
SCA among a large cohort of dialysis 
patients from 2002 to 2005. Among 43,200 
DaVita / Gambro dialysis patients, 784 wit-
nessed SCAs were documented for an 
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event rate of 4.5 per 100,000 dialysis ses-
sions, or 1 in 142 patient-years. After 
exclusions, 502 SCA patients were 
matched to 1632 age- and dialysis vintage-
matched controls. Th e authors found that 
dialysate potassium prescriptions less than 
2.0 mequiv. per liter were associated with 
a 2.06-fold (confi dence interval 1.48 – 2.86) 
greater probability of SCA, and low dia-
lysate calcium prescriptions less than 2.5 
mequiv. per liter were associated with a 
1.88-fold (confi dence interval 1.28 – 2.76) 
greater probability of SCA events, in com-
parison with matched controls in adjusted 
analysis. Greater ultrafiltrate volume 
removed during the dialysis session and a 
history of use of anti-arrhythmic drugs 
were also associated with greater odds of 
SCA, while serum calcium, phosphate, 
and parathyroid levels and history of car-
diovascular disease were not. Th e authors 
confi rmed that malnutrition (as deter-
mined by low serum albumin), lower 
serum creatinine, and lower levels of 
hemoglobin were also independently 
associated with an increased risk of an 
SCA event. 
 Th e authors also evaluated predialysis 
serum potassium levels and odds of SCA 
and found that many of the patients on 
lower-potassium baths also had low 
serum potassium levels at the most prox-
imally recorded laboratory test. SCA risk 
was also shown to have a U-shaped dis-
tribution compared with the level of 
serum potassium; for example, potassium 
levels lower and higher than 5.1 mequiv. 
per liter were associated with greater 
probability of SCA. In this regard, the 
authors found that an interaction or eff ect 
modification existed between serum 
potassium and dialysate potassium level 
for low serum and dialysate potassium, 
which diff ered for those with higher levels 
of serum potassium, particularly serum 
levels above 6.0 mequiv. per liter. The 
authors state that they did not fi nd any 
benefi t of prescribing a dialysis potassium 
level less than 2.0 mequiv. per liter; how-
ever, they did not prove that there was 
harm in low dialysate potassium at a 
higher level of serum potassium greater 
than 6.0 mequiv. per liter. 
 Th e results of Pun  et al. 20 are notewor-
thy and may have signifi cant repercus-
sions for dialysis-unit policy. Dialysis 
units and nephrologists should be more 
cognizant of low-predialysis-potassium 
baths and should consider adjusting dial-
ysis potassium baths accordingly. Aft er 
Karnik and colleagues published their 
seminal paper, 6 many dialysis units elim-
inated 0-mequiv.-per-liter-potassium 
dialysate baths because of concern about 
increased risk of SCA. Pun  et al. 20 go a 
step further and raise the issue of whether 
patients should be dialyzing on any potas-
sium bath less than 2.0 mequiv. per liter. 
Th is would have signifi cant ramifi cations 
for home-based therapies, where 1K   +  
baths are the norm, and possibly for noc-
turnal dialysis as well, as low potassium 
exposure would be longer and the risk of 
SCA potentially greater in dialyzing 
against a low-potassium dialysate. Hope-
fully, data from the Frequent Hemodi-
alysis Network randomized trial will help 
to clarify these concerns. 21 
 Additional limitations of the paper by 
Pun  et al. 20 should be noted. As the 
authors state, no labs were drawn the day 
of the SCA event, and hospitalizations 
proximal to the event are not known; 
thus, it is diffi  cult to know whether there 
may be additional reasons for a low-
potassium bath or increased risk of SCA. 
In addition, there is no information on 
diff erence in length of time of dialysis 
exposure between case and control. Th is 
information might help determine 
whether the length of time of exposure 
to low-K   +   dialysate is an additional incit-
ing factor for SCA. Th e authors found 
negative associations with some common 
medications, such as anti-arrhythmic 
medication, angiotensin-converting 
enzyme inhibitors, and angiotensin 
receptor blockers, which they correctly 
state are probably due to bias by indica-
tion. Additionally, the authors did not 
evaluate potential interactions between 
low calcium and dialysate potassium, which 
are two potential risk factors for SCA that 
may have a synergistic negative effect 
on cardiac membrane excitability. Finally, 
case-control studies are observational 
studies that best approximate randomized 
controlled trials; however, causality should 
still be cautiously interpreted. 
 In conclusion, Pun  et al. 20 present an 
interesting and important paper on 
potentially modifi able risk factors for 
SCA that may have signifi cant ramifi ca-
tions for hemodialysis patients in the 
United States and worldwide. Survival of 
cardiac arrest remains abysmal for dialy-
sis patients, and only 15 % of patients 
who have a cardiac arrest survive a year 
in the best of circumstances. 3 Prevention 
of this catastrophic outcome should be 
sought, and measures aimed to reduce 
modifi able risk factors should be under-
taken (Table 1). Ultimately, nephrolo-
gists have control over the dialysis 
prescription and should be aware of low 
as well as high levels. Perhaps dialysis 
 Table 1  |  Modifi able risk factors for prevention of sudden cardiac arrest in 
hemodialysis patients 
 Risk factor  Possible solution 
 Low predialysis serum potassium  Use dialysate algorithm to automatically 
adjust dialysate potassium bath 
 Low dialysate potassium concentration  Remove 0- and 1-mequiv.-per-liter-potassium 
dialysate baths from dialysis units 
 Low dialysate calcium concentration  Remove low-calcium dialysate baths below 2.0 
mequiv. per liter 
 High serum potassium  Adjust dialysate potassium and check potassium 
during the run 
 Rapid fl uid shifts during dialysis  Limit upper-range amount of fl uid removal 
per hour or per run; consider short daily or 
nocturnal dialysis 22  
 Hospitalization / acute events  Reevaluate serum electrolytes, dialysate 
potassium / calcium, and volume status after 
acute events 22  
 Cardioprotective medications  Randomized controlled trial data needed 
 Automatic defi brillators, implantable defi brillators  More data needed 
 Reference: Ostermann. 22 
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centers need to have more actionable 
algorithms to monitor and decrease 
exposure to low dialysate potassium and 
calcium levels, and more diligence is 
needed on the part of clinicians regard-
ing monitoring and adjustment of the 
dialysate prescription. Finally, more in-
depth and mechanistic research is 
needed to evaluate potential SCA eti-
ologies whereby eff ective interventions 
can be developed to prevent SCA in 
hemodialysis patients. Mortality rates 
remain unconscionably high for dialysis 
patients, and we, the nephrology com-
munity, must do all that is possible to 
prevent this deadly outcome. 
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 Experimental acute kidney injury (AKI) 
is accompanied by the death of renal 
tubule epithelial cells, and the degree of 
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renal dysfunction correlates with the 
extent of injury. In ischemic and cispla-
tin-induced AKI, cells of the terminal 
portion of the proximal tubule, which 
are most prominently involved, undergo 
necrosis while scattered cells through-
out the nephron undergo apoptosis. 
How these cells die is the topic of active 
research, but recent focus has placed a 
major emphasis on the cells that medi-
ate innate and  adoptive immunity in the 
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 Experimental acute kidney injury (AKI) is accompanied by the death of 
renal tubule epithelial cells, necrosis and apoptosis of the terminal 
portion of the proximal tubule, and apoptosis in the distal nephron. 
While immune competent cells invading the kidney play a role in such 
cell death, intervention in these processes only partially ameliorates the 
extent of cell death. Given the results of Linkermann  et al. in this issue 
of  KI , an epithelium-derived component of immune mediated cell death 
must now be strongly considered. 
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